RAPT Therapeutics, Inc. today reported financial results for the fourth quarter ended December 31, 2019 and provided an update on recent operational and business progress. “2019 was an espe
SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter ended December 31, 2019 and provided an update on recent operational and business progress.
“2019 was an especially productive year for RAPT with the completion of our initial public offering and the generation of encouraging early clinical data for our two lead immunology-based programs: FLX475 for the treatment of multiple cancers and RPT193 for the treatment of atopic dermatitis and other allergic inflammatory diseases,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. “In addition, we partnered with Hanmi for FLX475 in Asia, a region with a high prevalence of ‘charged’ tumors, and we strengthened our balance sheet substantially with our follow-on offering in February 2020.”
Dr. Wong continued, “For our ongoing Phase 1/2 study of FLX475, we continue to enroll and treat patients with multiple types of advanced cancer, though we are monitoring the impact of COVID-19 on our clinical trial sites both within and outside of the U.S. Because of the life-threatening nature of the cancers, we are working site by site to ensure that patients receive treatment and follow up as close to protocol-specified intervals as feasible. Our primary objective is patient safety and we will adapt to local circumstances as needed.
“For RPT193, we successfully completed the healthy volunteer portion of the study. We have made the decision to pause the enrollment of patients with atopic dermatitis in the Phase1b portion of our clinical study for RPT193 in an effort to support clinicians and healthcare facilities that are prioritizing the fight against COVID-19, while safeguarding the health and safety of patients and clinicians who would be involved in our trial. We intend to resume enrollment as soon as practical once we expect patients can be treated and followed up consistently under safer public health conditions.”
Financial Results for the Fourth Quarter and Full Year Ended December 31, 2019
Fourth Quarter Ended December 31, 2019
Net loss for the fourth quarter of 2019 was $13.2 million, compared to $9.4 million for the fourth quarter of 2018.
Research and development expenses for the fourth quarter of 2019 were $10.2 million, compared to $8.4 million for the same period in 2018. The increase was primarily due to clinical costs related to the advancement of RPT193 and FLX475 as well as the personnel costs associated with these studies offset by outsourced research and development and lab supplies.
General and administrative expenses for the fourth quarter of 2019 were $2.6 million, compared to $1.3 million for the same period in 2018. The increase was due to an increase in consulting costs as well as accounting and audit-related costs as well as other expenses associated with being a public company.
Full Year Ended December 31, 2019
Net loss for the year ended December 31, 2019 was $43.0 million, compared to $36.1 million for the same period in 2018.
Research and development expenses for the year ended December 31, 2019 were $34.9 million, compared to $31.8 million for the same period in 2018. The increase was primarily due to increases in costs relating to the clinical development of RPT193 and FLX475, facilities and personnel, offset by decreases in costs relating to lab supplies and outsourced research and development.
General and administrative expenses for the year ended December 31, 2019 were $8.7 million, compared to $5.2 million for the same period in 2018. The increase was primarily due to increases in professional service fees related to preparations for our initial public offering.
As of December 31, 2019, we had cash and cash equivalents of $77.4 million. In February 2020, we received net proceeds of approximately $69.7 million resulting from our follow-on public offering of 2,500,000 shares of common stock.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including general control nonderepressible 2 (GCN2) and hematopoietic progenitor kinase 1 (HPK1), that are in the discovery stage of development.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the impact of COVID-19 on the clinical development of FLX475 and RPT193 and the anticipated timing of clinical data. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Form 10-K expected to be filed with the Securities and Exchange Commission on or about March 30, 2020 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.
RAPT Media Contact:
Angela Bitting
media@rapt.com
(925) 202-6211
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
| Statement of Operations | ||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||
| December 31, | December 31, | |||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||
| Operating expenses: | ||||||||||||||
| Research and development | $ | 10,190 | $ | 8,380 | $ | 34,910 | $ | 31,767 | ||||||
| General and administrative | 2,625 | 1,291 | 8,719 | 5,180 | ||||||||||
| Total operating expenses | 12,815 | 9,671 | 43,629 | 36,947 | ||||||||||
| Loss from operations | 12,815 | 9,671 | 43,629 | 36,947 | ||||||||||
| Other income: | ||||||||||||||
| Other income, net | 259 | 241 | 1,292 | 800 | ||||||||||
| Net loss before taxes | 12,556 | 9,430 | 42,337 | 36,147 | ||||||||||
| Provision for taxes | 660 | — | 660 | — | ||||||||||
| Net loss | 13,216 | 9,430 | 42,997 | 36,147 | ||||||||||
| Other comprehensive income/(loss) | 7 | — | 24 | (4 | ) | |||||||||
| Total comprehensive loss | $ | 13,209 | $ | 9,430 | $ | 42,973 | $ | 36,151 | ||||||
| Net loss per share, basic and diluted | $ | 0.87 | $ | 13.56 | $ | 9.89 | $ | 58.09 | ||||||
| Weighted average number of shares used in computing net loss per share, basic and diluted | 15,255,118 | 695,544 | 4,346,400 | 622,289 | ||||||||||
| RAPT THERAPEUTICS, INC. | |||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||
| (In thousands) | |||||||||
| December 31, | December 31, | ||||||||
| 2019 | 2018 | ||||||||
| Assets | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 77,383 | $ | 63,798 | |||||
| Prepaid expenses and other current assets | 3,123 | 1,264 | |||||||
| Total current assets | 80,506 | 65,062 | |||||||
| Property and equipment, net | 3,707 | 4,159 | |||||||
| Other assets | 389 | 389 | |||||||
| Total assets | $ | 84,602 | $ | 69,610 | |||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 1,143 | $ | 1,771 | |||||
| Accrued expenses | 3,642 | 2,488 | |||||||
| Deferred revenue | 4,000 | - | |||||||
| Other current liabilities | 471 | 384 | |||||||
| Total current liabilities | 9,256 | 4,643 | |||||||
| Deferred rent, net of current portion | 2,225 | 969 | |||||||
| Commitments | |||||||||
| Convertible preferred stock | - | 161,111 | |||||||
| Stockholders’ equity (deficit): | |||||||||
| Preferred stock | - | - | |||||||
| Common stock | 2 | 1 | |||||||
| Additional paid-in capital | 235,049 | 22,441 | |||||||
| Related party promissory note for the purchase of common stock | - | (598 | ) | ||||||
| Accumulated other comprehensive income/(loss) | 20 | (4 | ) | ||||||
| Accumulated deficit | (161,950 | ) | (118,953 | ) | |||||
| Total stockholders’ (deficit) equity | 73,121 | (97,113 | ) | ||||||
| Total liabilities, convertible preferred stock and stockholders’ (deficit) | $ | 84,602 | $ | 69,610 | |||||
